RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease

Summary

The purpose of this clinical trial is to evaluate the clinical and cost effectiveness of Haploidentical Stem Cell Transplantation (SCT) for adults with severe sickle cell disease (SCD), who have failed other therapies or are intolerant of existing therapies or require chronic transfusions to prevent on-going complications of SCD.

Conditions

• Sickle Cell Disease

Interventions

PROCEDURE

Haploidentical stem cell transplantation

Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.

OTHER

Standard medical care

Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.

Sponsors & Collaborators

• King's College London

  collaborator OTHER

• University of Sheffield

  collaborator OTHER

• Sheffield Teaching Hospitals NHS Foundation Trust

  collaborator OTHER

• Imperial College Healthcare NHS Trust

  collaborator OTHER

• Guy's and St Thomas' NHS Foundation Trust

  collaborator OTHER

• University College London Hospitals

  collaborator OTHER

• Manchester University NHS Foundation Trust

  collaborator OTHER_GOV

• St George's University Hospitals NHS Foundation Trust

  collaborator OTHER

• Barts & The London NHS Trust

  collaborator OTHER

• National Institute for Health Research, United Kingdom

  collaborator OTHER_GOV

• King's College Hospital NHS Trust

  lead OTHER

Principal Investigators

• Ann-Marie Murtagh · King's College Hospitals NHS Foundation Trust

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-02-23

Primary Completion

2027-03-31

Completion

2027-03-31

Countries

• United Kingdom

Study Locations